Four cash routes remain when a plan will not pay for a GLP-1 prescribed for weight management: manufacturer direct self-pay pricing, a savings card if eligibility rules allow it, a different medication that the plan does cover, or a compounded product from a supervised practice. Which of them is open depends on why coverage is unavailable, not on the insurer’s name.
First establish whether it is an exclusion or a rejection
These two situations look identical at the pharmacy counter and lead to completely different next steps. A benefit exclusion means the employer or plan sponsor bought a plan that carves out anti-obesity medication as a category. Nothing about the prescription changes that. A rejection means the category exists but a specific condition was not met, such as a missing prior authorization, a step therapy requirement, or a quantity limit.
UnitedHealthcare administers thousands of distinct benefit designs, and coverage of weight management drugs is set at the plan and employer level rather than nationally. The only reliable answer comes from the plan’s own summary of benefits and the current drug list attached to that specific plan, both of which are keyed to the member ID. Many of those plans use Optum Rx as the pharmacy benefit manager, so the drug list may sit under that name rather than the insurer’s.
Working out which of the two situations applies is easier with a reference in hand. Several telehealth providers now publish plain-language explainers on the subject, among them Ro, Hims and Hers, and Henry Meds, and the HealthRX guide to GLP-1 insurance coverage walks through prior authorization and category exclusions in the order a member runs into them.
If the answer is a category exclusion, appealing is usually a poor use of time and the cash routes below are the real decision. If the answer is a rejection on criteria, fixing the paperwork is normally cheaper than paying cash.
Manufacturer self-pay programs reset the baseline
Both Novo Nordisk and Eli Lilly now sell their branded weight management drugs directly to people paying cash, at prices far below the list figures that dominated coverage arguments a few years ago. These programs are the first thing to price, because they removed the situation where an uninsured patient faced a four-figure monthly bill with no alternative.
They come with conditions worth reading closely. Refill timing rules are common, pricing often varies by dose or vial format, and staying enrolled continuously can matter more than the headline number. A price quoted for the starting dose is not necessarily the price at a maintenance dose, and the sustainable figure is the one that determines whether treatment continues past month four.
Savings cards do less than the advertisement suggests
Manufacturer copay cards are widely misread as cash discounts. Most of them assume the person already has commercial insurance that covers the drug, with the card reducing whatever copay remains. Someone whose plan excludes the category typically does not qualify for the largest advertised reduction. People with Medicare, Medicaid, TRICARE or other government coverage are generally excluded from commercial copay assistance entirely.
The useful step is to read the eligibility conditions before treating an advertised figure as a personal price. The number that matters is the one the card produces given a specific coverage status.
What the routes actually compare on
| Route | What sets the price | Who it fits | Main limitation |
|---|---|---|---|
| Manufacturer self-pay | Fixed cash price set by the maker | Anyone paying out of pocket | Refill timing and dose conditions |
| Copay savings card | Remaining copay after plan payment | Commercially insured with coverage | Excludes government insurance |
| Covered alternative drug | Formulary tier and deductible | Plans that cover some obesity drugs | May require step therapy first |
| Compounded medication | Pharmacy and practice pricing | People with a category exclusion | Not an FDA-approved product |
Where compounded medication fits
Compounded semaglutide and tirzepatide are prepared by compounding pharmacies rather than manufactured under an approved application. The FDA does not review them for safety, effectiveness or quality, and they are not FDA-approved products. That is a material difference from the branded drugs, not a technicality, and it is the honest starting point for anyone considering this route. Reported problems have included dosing errors caused by unfamiliar vial and syringe formats.
What the route offers is a predictable monthly cash price with no plan involvement and no authorization to renew. Practices operating under clinician supervision, among them FormBlends, quote one monthly figure covering the medication and the visits together, which is the arrangement to look for rather than a storefront that ships on request. Anything that sells without an individual clinical assessment should be treated as a red flag.
FDA has also stated that the shortages that originally justified large-scale compounding of these molecules were resolved, which narrowed the legal basis for producing copies. Anyone choosing this route should understand that the regulatory position is not static.
Older drugs are still real options
The conversation has narrowed to two molecules in a way that does not reflect the evidence. Liraglutide is available as a generic in the United States and has trial data behind it, though a head-to-head trial found weekly semaglutide produced greater weight reduction than daily liraglutide. Phentermine, phentermine-topiramate and naltrexone-bupropion all remain in clinical guidelines and cost a fraction of the newer injectables.
Current obesity pharmacotherapy guidance treats drug selection as a match between the patient’s conditions and the drug’s profile rather than a ranking. A cheaper drug that a person can take for three years frequently beats a better drug they abandon after two months on cost.
Pretax accounts change the effective price
Health savings accounts and flexible spending accounts can generally be used for prescribed weight management medication, which reduces the real cost by whatever a person’s marginal tax rate is. This is the least discussed lever and one of the few that works regardless of which route is chosen. Plan documents and account administrators set the substantiation rules, so confirming eligibility before spending down an account balance avoids a reimbursement dispute later.
Frequently asked questions
Does switching from one GLP-1 to another help if a claim is rejected?
Only if the rejection was drug-specific, such as a non-formulary status or a quantity limit. When the plan excludes anti-obesity medication as a benefit category, the exclusion applies to the whole category and switching molecules produces the same result at the counter.
Is a manufacturer self-pay price the same every month?
Not necessarily. Several programs tie the price to dose, to vial or pen format, and to filling refills within a set window. Missing that window can move a person to a higher price, so the maintenance dose figure is the one worth planning around.
Can a GLP-1 be covered for something other than weight loss?
Coverage depends on the medically accepted indication a plan recognizes and on documentation supporting it. Some of these molecules carry approved indications beyond weight management, and those are adjudicated under different rules. The plan’s own criteria document is the only place that answer exists.
Is compounded medication simply a cheaper version of the brand?
No. It is prepared by a compounding pharmacy and has not been through the approval process that generated the published trial evidence for the branded products. It may contain the same active molecule, but the regulatory assurance behind it is not equivalent.
What matters most when picking a cash route?
The price a person can pay every month for as long as treatment continues. Weight regain after stopping is well documented, so an interrupted course at a low headline price usually performs worse than a slightly higher price that is sustainable.
